Patents Assigned to Daiichi Pharmaceutical Co., LTD
-
Publication number: 20140225303Abstract: This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than the first-mentioned sugar alcohol and/or saccharide and then subjecting the resulting powder to combined processing of compression and heating. This invention can provide medicinal compositions, which rapidly disintegrate when taken in the oral cavity without water and are excellent in handling ease owing to exhibition of sufficient hardness upon their production, transportation and use in usual manner, and can also provide a process for the production of the medicinal compositions, which is simpler and can avoid contact between an active ingredient and water as needed.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroaki NAKAGAMI, Yoshio Kuno
-
Publication number: 20120232288Abstract: An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.Type: ApplicationFiled: April 25, 2012Publication date: September 13, 2012Applicant: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi TAKAHASHI, Hiroaki INAGAKI, Satoshi KOMORIYA, Makoto TAKEMURA, Rie MIYAUCHI
-
Patent number: 8211910Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.Type: GrantFiled: April 13, 2009Date of Patent: July 3, 2012Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
-
Publication number: 20110166131Abstract: A quinolone antibacterial compound, or a salt or hydrate of the compound, for the treatment of infectious diseases, which exhibit potent antibacterial activity and higher selective toxicity against Gram-positive and Gram-negative bacteria, which do not cause side effects (e.g.Type: ApplicationFiled: March 11, 2011Publication date: July 7, 2011Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hisashi TAKAHASHI, Junichi Kuroyanagi, Rie Miyauchi, Masatoshi Nagamochi, Makoto Takemura, Isao Hayakawa
-
Publication number: 20110150974Abstract: A medicament used for prophylactic and/or therapeutic treatment of xerostomia, which is in the form for oral mucosal administration comprising a spirooxathiolane quinuclidine derivative represented by the following general formula (I) or an acid addition salt thereof: [Formula 1] (wherein R1 and R2 may be the same or different, and independently represent a hydrogen atom, an alkyl group, a cyclopentyl group, a cyclohexyl group, a monoaryl- or diaryl-substituted methylol group, or an aryl-substituted alkyl group) as an active ingredient.Type: ApplicationFiled: August 4, 2005Publication date: June 23, 2011Applicants: DAIICHI PHARMACEUTICAL CO., LTD., SAITAMA DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Noriko Nakajima, Norihiro Shinkai, Hitoshi Yamauchi, Masahiko Kikuchi
-
Patent number: 7939100Abstract: The present invention provides a tulobuterol adhesive patch comprising (a) a support, (b) an acrylic pressure-sensitive adhesive layer containing the percutaneously absorbing drug tulobuterol and if necessary a lipophilic oily plasticizer, and (c) a release liner, laminated in that order, wherein the acrylic pressure-sensitive adhesive is a copolymer obtained by copolymerizing an acrylic monomer which is acetoacetoxyalkyl (meth) acrylate with one or more other vinyl monomers, to yield a tulobuterol adhesive patch with excellent release and skin permeability of tulobuterol from the pressure-sensitive adhesive layer, low skin irritation and excellent safety.Type: GrantFiled: December 21, 2004Date of Patent: May 10, 2011Assignee: Saitama Daiichi Pharmaceutical Co., Ltd.Inventors: Naohisa Kawamura, Hidenori Sawada, Yoshiki Sugizaki, Takashi Saitoh
-
Patent number: 7935824Abstract: The invention relates a compound represented by the formula (1): Q1-Q2-C(?O)—N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism.Type: GrantFiled: May 13, 2009Date of Patent: May 3, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Toshiharu Yoshino, Tsutomu Nagata, Noriyasu Haginoya, Kenji Yoshikawa, Hideyuki Kanno, Masatoshi Nagamochi
-
Patent number: 7932271Abstract: Provided is a compound capable of inhibiting production or secretion of ? amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.Type: GrantFiled: June 29, 2004Date of Patent: April 26, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hideki Kubota, Takanori Yasukouchi, Satoru Miyauchi, Kayoko Motoki, Masanori Saito, Hitoshi Iimori
-
Patent number: 7915418Abstract: Provision of a commercially advantageous method for producing an intermediate which is important for producing the antibacterial and which has a mother nucleus common to the antibacterial, and intermediates produced by such method. A method for producing a compound represented by formula (VI): which comprises the steps of treating a compound represented by formula (IV): with a base in the presence of a base to produce a compound represented by formula (V): and hydrolyzing this compound; a compound represented by formula (II): a compound represented by formula (Ia): a compound represented by formula (V): and a compound represented by formula (VI).Type: GrantFiled: June 4, 2004Date of Patent: March 29, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Makoto Muto, Manabu Miura, Yutaka Kitagawa
-
Patent number: 7902226Abstract: 3-(1-Aminocycloalkyl)pyrrolidinyl-substituted-6-dehalodeno(hydrogen-substituted)quinolon carboxylic acid derivatives having specific substituents as represented by the following formula (I), its salts, and hydrates thereof exhibit a broad and potent antibacterial activity on gram-negative and gram-positive bacteria, in particular, resistant bacteria typified by gram-positive cocci, including MRSA, PRSP and VRE. Thus these compounds are usable as drugs.Type: GrantFiled: December 26, 2006Date of Patent: March 8, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi Takahashi, Rie Miyauchi, Masao Itoh, Makoto Takemura, Isao Hayakawa
-
Publication number: 20110054177Abstract: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid of formula (5) or a salt thereof, is prepared by reacting reacting 2-bromo-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (3) or a salt thereof, with a metal cyanide, to obtain 2-cyano-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (4) or a salt thereof, and hydrolyzing the 2-cyano-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (4) or a salt thereof.Type: ApplicationFiled: November 8, 2010Publication date: March 3, 2011Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi NAGASAWA, Koji Sato, Tsutomu Yagi, Yasuo Kitani
-
Patent number: 7893279Abstract: The present invention provides a VLA-4 inhibitor having high water-solubility and excellent long-term stability; i.e., sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.Type: GrantFiled: October 7, 2009Date of Patent: February 22, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Makoto Ono, Shigeru Noguchi
-
Patent number: 7723524Abstract: To provide a quinolone antibacterial drug and a therapeutic agent for infectious diseases, which exhibit potent antibacterial activity on Gram-positive and Gram-negative bacteria and which is highly safe. A compound represented by the following formula (1): (wherein R1 represents a C3-C6 cycloalkyl group which may have a substituent or the like; R2 represents a hydrogen atom or the like; R3 and R4 each independently represent a hydrogen atom or a C1-C6 alkyl group, or a substituted carboxyl group derived from an amino acid, a dipeptide, or a tripeptide, and, in the case where each of R3 and R4 represents a C1-C6 alkyl group, the alkyl group may be substituted by one or more atoms or groups selected from among a hydroxyl group, a halogen atom, a C1-C6 alkylthio group, and a C1-C6 alkoxy group; and n denotes an integer of 1 to 3), a salt thereof, and a hydrate of the compound or the salt. Also, antibacterial drugs and therapeutic agents for infectious diseases are prepared.Type: GrantFiled: September 29, 2004Date of Patent: May 25, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi Takahashi, Rie Miyauchi, Makoto Takemura
-
Patent number: 7709028Abstract: A particulate containing a pantethine, a light anhydrous silicic acid and a microcrystalline cellulose, in which the total content of the light anhydrous silicic acid the microcrystalline cellulose amounts to a quantity that yields a 0.6 or higher adsorptivity. The present pantethine-containing particulate has a good flowability and an adequate particle size providing excellent handling properties. It is free from impediments such as blocking, and has a good storage stability.Type: GrantFiled: September 29, 2003Date of Patent: May 4, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Motonori Kidokoro, Yasuhiro Tsutsumi, Mitsumasa Nada
-
Patent number: 7705196Abstract: Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg; an agent for inhibiting tumor formation or an agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP; a method of enhancing the expression and/or function of sFRP, comprising enhancing the expression and/or function of Dlg; a method of inhibiting tumor formation or a method of preventing and/or treating a tumor disease, comprising using the aforementioned enhancing agent or the aforementioned enhancing method; a non-human mammal that is deficient in one or both of Dlg alleles; a cell originating in the mammal; a method of identifying a compound, comprising using the mammal or the cell; and a method of examining a tumor tissue orType: GrantFiled: March 30, 2005Date of Patent: April 27, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Tetsu Akiyama, Takefumi Ishidao, Tomoiki Aiba
-
Publication number: 20100099660Abstract: A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing is provided.Type: ApplicationFiled: December 16, 2009Publication date: April 22, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Publication number: 20100093785Abstract: A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-(R2)T1Q4 ??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.Type: ApplicationFiled: December 30, 2008Publication date: April 15, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Patent number: 7691894Abstract: The present invention provides a VLA-4 inhibitor having high water-solubility and excellent long-term stability; i.e., sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.Type: GrantFiled: July 23, 2004Date of Patent: April 6, 2010Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Makoto Ono, Shigeru Noguchi
-
Publication number: 20100080847Abstract: This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than the first-mentioned sugar alcohol and/or saccharide and then subjecting the resulting powder to combined processing of compression and heating. This invention can provide medicinal compositions, which rapidly disintegrate when taken in the oral cavity without water and are excellent in handling ease owing to exhibition of sufficient hardness upon their production, transportation and use in usual manner, and can also provide a process for the production of the medicinal compositions, which is simpler and can avoid contact between an active ingredient and water as needed.Type: ApplicationFiled: December 4, 2009Publication date: April 1, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroaki Nakagami, Yoshio Kuno
-
Publication number: 20100076202Abstract: The present invention provides an advantageous method for producing an intermediate which is useful for production of a compound which exhibits excellent VLA-4 inhibitory effect and safety. An intermediate (14) is produced through the following reaction scheme.Type: ApplicationFiled: December 1, 2009Publication date: March 25, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Yoshihiro TAKAYANAGI, Toshihide Yamada, Yukito Furuya, Yoshiyuki Yoneda